Last update
3/18/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
USERS' SCORE
Good
Based on 5 Reviews
8.2
Supplement Facts
Serving Size: 1 Veggie Capsule
Serving Per Container: 60
Amount Per Serving
%DV
Vitamin K2 (from MenaQ7® Menaquinone, MK-7)
45 mcg
38%
Top Medical Research Studies
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
Most Useful Reviews
9
Strengthened heart
After taking K2, I've noticed my teeth are stronger and my heart feels more robust. I will continue with Doctor's Best for its benefits.
Read More
7.5
Heart and vessel health
1 people found this helpful
I have used Vitamin K for quite some time and find it excellent for heart and blood vessel health.
Read More
7.5
Heart health support
This K2 supplement is fantastic for heart health. The dosage of 45mcg is just right, and the pills are easy to swallow.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
- All Researches
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Strengthened heart
After taking K2, I've noticed my teeth are stronger and my heart feels more robust. I will continue with Doctor's Best for its benefits.
Read More
7.5
Heart and vessel health
1 people found this helpful
I have used Vitamin K for quite some time and find it excellent for heart and blood vessel health.
Read More
7.5
Heart health support
This K2 supplement is fantastic for heart health. The dosage of 45mcg is just right, and the pills are easy to swallow.
Read More
7.5
Quality supplement
I've been using this for some time now, appreciating the dosage and quality. It's beneficial for a healthy heart, and I'm continually reading about its advantages.
Read More
6
Heart disease prevention
I take K2 as it reduces the risk of heart disease.
Read More
Frequently Asked Questions
9
Strengthened heart
After taking K2, I've noticed my teeth are stronger and my heart feels more robust. I will continue with Doctor's Best for its benefits.
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
References
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. 10.1161/JAHA.124.038834
- Babadagli HE, Ye J, Chen J, Turgeon R, Wang EH. Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review. Open Heart. 2025;12. 10.1136/openhrt-2024-003158
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Macias-Cervantes HE, Ocampo-Apolonio MA, Guardado-Mendoza R, Baron-Manzo M, Pereyra-Nobara TA, et al. Effect of vitamin K1 supplementation on coronary calcifications in hemodialysis patients: a randomized controlled trial. J Nephrol. 2025;38:511. 10.1007/s40620-024-02154-9
- Preda A, Falasconi G, Melillo F, Margonato D, Posteraro GA, et al. Left atrial appendage closure in patients with failure of anticoagulation therapy: A multicenter comparative study on the hybrid strategy using DOACs and VKAs. Int J Cardiol. 2025;421:132875. 10.1016/j.ijcard.2024.132875
Data last updated:
